Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

ASPS Clinical Practice Guideline Summary on Reduction Mammaplasty

Kalliainen, Loree K. M.D.ASPS Health Policy Committee

Plastic and Reconstructive Surgery: October 2012 - Volume 130 - Issue 4 - p 785–789
doi: 10.1097/PRS.0b013e318262f0c0
Breast: Outcomes Article
Buy
Discussion

Summary: In May of 2011, the Executive Committee of the American Society of Plastic Surgeons approved an evidence-based guideline on reduction mammaplasty developed by the American Society of Plastic Surgeons Health Policy Committee. The guideline addresses six clinical questions: procedural efficacy as noted by relief of symptoms, resection weight, the impact of body mass index on surgical complications, use of prophylactic antibiotics, use of drains, and effect on quality of life. The evidence indicates that resection volume is not correlated directly to the degree of postoperative symptom relief. Increased breast resection weight may increase the risks of complication. The evidence is inconclusive on whether increased body mass index is associated with increased risk of complications. Perioperative antibiotics may reduce the risk of infection associated with reduction mammaplasty, and in standard reduction mammaplasty procedures without liposuction, the use of drains is not beneficial. Reduction mammaplasty has been shown to improve quality of life.

Arlington Heights, Ill.

From the American Society of Plastic Surgeons.

Received for publication April 17, 2011; accepted April 23, 2012.

A complete list of the authors of this article is as follows: Loree K. Kalliainen, M.D., Chair; Dale C. Vidal, M.D., Past Chair; Peter Aldea, M.D.; Steven Bonawitz, M.D.; Kevin Chung, M.D.; Gary Culbertson, M.D.; Lynn Damitz, M.D.; Leland Deane, M.D.; Richard Greco, M.D.; Christopher Hussussian, M.D; Sami Khan, M.D.; Bill Kortesis, M.D.; Gordon Lee, M.D.; Stephen Metzinger, M.D.; Galen Perdikis, M.D.; Adam Ravin, M.D.; Neal Reisman, M.D.; Karie Rosolowski, M.P.H.; Loren Schechter, M.D.; DeLaine Schmitz, R.N, M.S.H.L.; Alexander Spiess, M.D.; Jennifer Swanson, M.Ed.; and William Wooden, M.D.

Disclosure:Dale C. Vidal, M.D., Past Chair, has a consultant relationship with Mentor Corporation/Ethicon/Johnson and Johnson. Leland Deane, M.D., has a consultant relationship with Covidien. Richard Greco, M.D., has a speaker relationship with Mentor Corporation/Ethicon/Johnson and Johnson and a shareholder relationship with Obagi Medical Products. Gordon Lee, M.D., has a consultant relationship with Covidien, Inc., LifeCell Corporation/KCI, and TEI, Inc. Loree Kalliainen, M.D., Chair, and the other authors have no financial interest to disclose.

Karie Rosolowski, M.P.H., 444 East Algonquin Road, Arlington Heights, Ill. 60005-4664

©2012American Society of Plastic Surgeons